Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors
Neoangiogenesis has been demonstrated in chondrosarcoma. Anti-angiogenic therapies are being tested in clinical trials for chondrosarcomas. Studies of the underlying mechanisms have been performed almost exclusively in cell lines. We immunostained 20 samples of chondrosarcoma and 20 samples of enchondromas with antibodies against hypoxia-inducible factor 1-alpha (HIF-1-alpha) and vascular endothelial growth factor (VEGF). The immunohistochemical staining of HIF-1-alpha and VEGF were highly correlated. Enchondromas were HIF-1-alpha and VEGF negative, whereas all chondrosarcoma exhibited HIF-1-alpha and VEGF immunostaining. HIF-1-alpha/VEGF double positive cases were almost exclusively chondrosarcomas with a high tumor grade. We suggest that HIF-1-alpha is a marker of malignancy in chondrosarcomas that correlates with tumor neo-angiogenesis. Our findings also suggest that a HIF-1-alpha/VEGF angiogenic pathway may exist in chondrosarcoma in vivo as in other malignant tumors. The inclusion of novel inhibitors to HIF-1-alpha and other factors may optimize anti-angiogenic interventions in chondrosarcoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Biotechnic & histochemistry : official publication of the Biological Stain Commission - 94(2019), 4 vom: 01. Mai, Seite 283-289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kouvaras, E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.08.2019 Date Revised 13.08.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10520295.2018.1556806 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29233706X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29233706X | ||
| 003 | DE-627 | ||
| 005 | 20231225072855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10520295.2018.1556806 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0974.xml |
| 035 | |a (DE-627)NLM29233706X | ||
| 035 | |a (NLM)30605014 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kouvaras, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.08.2019 | ||
| 500 | |a Date Revised 13.08.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Neoangiogenesis has been demonstrated in chondrosarcoma. Anti-angiogenic therapies are being tested in clinical trials for chondrosarcomas. Studies of the underlying mechanisms have been performed almost exclusively in cell lines. We immunostained 20 samples of chondrosarcoma and 20 samples of enchondromas with antibodies against hypoxia-inducible factor 1-alpha (HIF-1-alpha) and vascular endothelial growth factor (VEGF). The immunohistochemical staining of HIF-1-alpha and VEGF were highly correlated. Enchondromas were HIF-1-alpha and VEGF negative, whereas all chondrosarcoma exhibited HIF-1-alpha and VEGF immunostaining. HIF-1-alpha/VEGF double positive cases were almost exclusively chondrosarcomas with a high tumor grade. We suggest that HIF-1-alpha is a marker of malignancy in chondrosarcomas that correlates with tumor neo-angiogenesis. Our findings also suggest that a HIF-1-alpha/VEGF angiogenic pathway may exist in chondrosarcoma in vivo as in other malignant tumors. The inclusion of novel inhibitors to HIF-1-alpha and other factors may optimize anti-angiogenic interventions in chondrosarcoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chondrosarcoma | |
| 650 | 4 | |a HIF-1-alpha | |
| 650 | 4 | |a enchondroma | |
| 650 | 4 | |a hypoxia | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a vascular endothelial growth factor | |
| 650 | 7 | |a HIF1A protein, human |2 NLM | |
| 650 | 7 | |a Hypoxia-Inducible Factor 1, alpha Subunit |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 700 | 1 | |a Christoni, Z |e verfasserin |4 aut | |
| 700 | 1 | |a Siasios, I |e verfasserin |4 aut | |
| 700 | 1 | |a Malizos, K |e verfasserin |4 aut | |
| 700 | 1 | |a Koukoulis, G K |e verfasserin |4 aut | |
| 700 | 1 | |a Ioannou, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biotechnic & histochemistry : official publication of the Biological Stain Commission |d 1996 |g 94(2019), 4 vom: 01. Mai, Seite 283-289 |w (DE-627)NLM01263798X |x 1473-7760 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2019 |g number:4 |g day:01 |g month:05 |g pages:283-289 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10520295.2018.1556806 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2019 |e 4 |b 01 |c 05 |h 283-289 | ||